South and Central America accounted for a 2.8% share of global clinical trials activity in 2020, a decrease of 0.6% compared with a 3.4% average over the last ten-years, according to GlobalData.
In South and Central America, single country studies held a 49.3% share for all clinical trials in 2020, compared with the ten-year average of 44.6%. Multinational trials accounted for a 50.7% share in 2020 against an average of 55.4% in the last ten years.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials in South and Central America
Industry sponsored trials held a 64.3% share of all the clinical trials in South and Central America in 2020, a drop over their ten-year average of 65.2%. Non-industry sponsored trials accounted for a 35.7% share in 2020, up from an average of 34.8% in the last ten years.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
2020 industry sponsored clinical trials in South and Central America – Top therapy areas
Infectious Disease was the leading therapy area for industry sponsored clinical trials in South and Central America in 2020 with a 42.6% share, up from its ten-year average of 14.6%.
Oncology held a 25.7% share in 2020, up from its ten-year average of 23.0%.
In the third place was Respiratory with a 17.4% share in 2020, up from its ten-year average of 8.0%. Immunology recorded a 7.1% share in 2020, a drop over its ten-year average of 9.5%.
With a share of 6.5% in 2020, Central Nervous System witnessed a drop over its ten-year average of 10.4%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored clinical trials in South and Central America by top therapy areas
Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in South and Central America in 2020 with a 68.6% share, up from a ten-year average of 15.2%.
In the second place was Respiratory with a 14.5% share in 2020, which represented a rise over a ten-year average of 4.3%.
With a share of 11.4% in 2020, Central Nervous System witnessed a drop over its ten-year average of 23.4%. Cardiovascular held an 8.6% share in 2020, as against ten-year average of 13.4%.
Oncology held a 5.9% share, which was down from ten-year average of 10.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
2020 clinical trials in South and Central America by phase
In terms of phases, Phase III trials led the industry sponsored clinical trials in South and Central America in 2020, with a share of 57.2%, marking a drop over a ten-year average of 60.5%.
Phase II trials stood next with a 32.2% share in 2020, which was up against a ten-year average of 23.0%.
In the third place was Phase IV trials with a 5.8% share in 2020, down from its ten-year average of 12.5%.
Phase I trials held a 4.8% share in 2020, with a 0.8% rise over its ten-year average of 4.0%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
For non-industry sponsored clinical trials in South and Central America, Phase II trials held a leading share of 55.5% in 2020, up from its ten-year average of 50.2%.
In the second place was Phase III trials that held a 25.5% share in 2020 and saw a 7.1% rise over a ten-year average of 18.4%.
Phase IV trials stood at a 14.1% share, down against its ten-year average of 25.6%.
Phase I trials held a 5.0% share in 2020, down from its ten-year average of 5.8%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
